Nobilis Therapeutics is developing proprietary inhalation-based therapeutics using controlled self-administration of inert gases to address unmet medical need in the treatment of psychiatric and neurodegenerative diseases.

By leveraging data on more than 500 patients successfully treated for conditions ranging from panic disorder to autoimmune diseases, Nobilis has coupled its patent pending gas mixtures with a proprietary inhalational device to offer reproducible, standardized, and controlled patient exposure. The Company is currently advancing its technologies into human clinical trials.

Twitter Feed

Nobilis Therapeutics @NobilisTx
Xe added to propofol improves hemodynamic stability in patients undergoing OPCAB. Less Levophed means less CV risks https://t.co/5fOiCG1sJf
h J R
Nobilis Therapeutics @NobilisTx
https://t.co/KkTtL4A3Xs This is yet another indication that Xe a) is cytoprotective and b) may be beneficial in Rx of Parkinson's disease
h J R
Nobilis Therapeutics @NobilisTx
This is devastating. We hope that our approach to PTSD and suicidality will make a dent. https://t.co/UZY5RBFjNj
h J R
Nobilis Therapeutics @NobilisTx
We will do better than that!!! https://t.co/g4qimc2ubx
h J R